These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25066331)

  • 1. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.
    Asehnoune K; Seguin P; Allary J; Feuillet F; Lasocki S; Cook F; Floch H; Chabanne R; Geeraerts T; Roger C; Perrigault PF; Hanouz JL; Lukaszewicz AC; Biais M; Boucheix P; Dahyot-Fizelier C; Capdevila X; Mahe PJ; Le Maguet P; Paugam-Burtz C; Gergaud S; Plaud B; Constantin JM; Malledant Y; Flet L; Sebille V; Roquilly A;
    Lancet Respir Med; 2014 Sep; 2(9):706-16. PubMed ID: 25066331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study.
    Roquilly A; Mahe PJ; Seguin P; Guitton C; Floch H; Tellier AC; Merson L; Renard B; Malledant Y; Flet L; Sebille V; Volteau C; Masson D; Nguyen JM; Lejus C; Asehnoune K
    JAMA; 2011 Mar; 305(12):1201-9. PubMed ID: 21427372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotherapy for traumatic brain-injured patients--the Corti-TC trial: study protocol for a randomized controlled trial.
    Asehnoune K; Roquilly A; Sebille V;
    Trials; 2011 Oct; 12():228. PubMed ID: 21999663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial.
    Heming N; Renault A; Kuperminc E; Brun-Buisson C; Megarbane B; Quenot JP; Siami S; Cariou A; Forceville X; Schwebel C; Leone M; Timsit JF; Misset B; Benali MA; Colin G; Souweine B; Asehnoune K; Mercier E; Chimot L; Charpentier C; François B; Boulain T; Petitpas F; Constantin JM; Dhonneur G; Baudin F; Combes A; Bohé J; Loriferne JF; Cook F; Slama M; Leroy O; Capellier G; Dargent A; Hissem T; Bounab R; Maxime V; Moine P; Bellissant E; Annane D; ;
    Lancet Respir Med; 2024 May; 12(5):366-374. PubMed ID: 38310918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
    Nichol A; French C; Little L; Haddad S; Presneill J; Arabi Y; Bailey M; Cooper DJ; Duranteau J; Huet O; Mak A; McArthur C; Pettilä V; Skrifvars M; Vallance S; Varma D; Wills J; Bellomo R; ;
    Lancet; 2015 Dec; 386(10012):2499-506. PubMed ID: 26452709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial.
    Dahyot-Fizelier C; Lasocki S; Kerforne T; Perrigault PF; Geeraerts T; Asehnoune K; Cinotti R; Launey Y; Cottenceau V; Laffon M; Gaillard T; Boisson M; Aleyrat C; Frasca D; Mimoz O;
    Lancet Respir Med; 2024 May; 12(5):375-385. PubMed ID: 38262428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.
    Annane D; Sébille V; Charpentier C; Bollaert PE; François B; Korach JM; Capellier G; Cohen Y; Azoulay E; Troché G; Chaumet-Riffaud P; Bellissant E
    JAMA; 2002 Aug; 288(7):862-71. PubMed ID: 12186604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
    François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
    Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
    Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
    Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oropharyngeal povidone-iodine preventive oral care on ventilator-associated pneumonia in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial.
    Seguin P; Laviolle B; Dahyot-Fizelier C; Dumont R; Veber B; Gergaud S; Asehnoune K; Mimoz O; Donnio PY; Bellissant E; Malledant Y; ;
    Crit Care Med; 2014 Jan; 42(1):1-8. PubMed ID: 24105456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of pneumonia after severe traumatic brain injury.
    Barbier F; Sonneville R; Boulain T
    Lancet Respir Med; 2014 Sep; 2(9):674-5. PubMed ID: 25066334
    [No Abstract]   [Full Text] [Related]  

  • 13. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
    Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
    Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
    Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial.
    Temkin NR; Anderson GD; Winn HR; Ellenbogen RG; Britz GW; Schuster J; Lucas T; Newell DW; Mansfield PN; Machamer JE; Barber J; Dikmen SS
    Lancet Neurol; 2007 Jan; 6(1):29-38. PubMed ID: 17166799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.